尽管开发了多种治疗策略，但血液恶性肿瘤仍然是治疗挑战。磷脂酰肌醇-3 激酶 (PI3K)/蛋白激酶 B/雷帕霉素哺乳动物靶标 (PI3K/Akt/mTOR) 信号通路在调节许多细胞功能（包括细胞周期、增殖、静止和寿命）中发挥着核心作用。因此，该途径的失调是癌发生的一个特征。 PI3K/Akt/mTOR 信号传导增强可增强癌细胞的增殖、生长以及对化疗和免疫治疗的抵抗力。在各种类型的癌症中都发现了该通路的过度激活，包括急性和慢性白血病。 PI3K/Akt/mTOR通路抑制剂自2014年以来一直用于白血病治疗，其中一些在临床试验中改善了治疗结果。最近，已经开发出新型 PI3K/Akt/mTOR 信号传导抑制剂，并在临床前和临床模型中进行了测试。在这篇综述中，我们概述了 PI3K/Akt/mTOR 信号通路在血液恶性肿瘤细胞中的作用，并收集了有关该通路抑制剂的信息，这可能为白血病提供新的治疗机会。

Blood malignancies remain a therapeutic challenge despite the development of numerous treatment strategies. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway plays a central role in regulating many cellular functions, including cell cycle, proliferation, quiescence, and longevity. Therefore, dysregulation of this pathway is a characteristic feature of carcinogenesis. Increased activation of PI3K/Akt/mTOR signaling enhances proliferation, growth, and resistance to chemo- and immunotherapy in cancer cells. Overactivation of the pathway has been found in various types of cancer, including acute and chronic leukemia. Inhibitors of the PI3K/Akt/mTOR pathway have been used in leukemia treatment since 2014, and some of them have improved treatment outcomes in clinical trials. Recently, new inhibitors of PI3K/Akt/mTOR signaling have been developed and tested both in preclinical and clinical models. In this review, we outline the role of the PI3K/Akt/mTOR signaling pathway in blood malignancies' cells and gather information on the inhibitors of this pathway that might provide a novel therapeutic opportunity against leukemia.